pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 1·1 min read
save

CDC prioritizes containing Ebola spread as Trump administration proposes grant overhaul

Jun 1, 2026·read at STAT ↗Neutral

The CDC announced that stopping the spread of Ebola remains its top priority, emphasizing containment measures as the virus continues to pose a threat.

In parallel, the Trump administration released a broad proposal to change how federal grants are administered, aiming to increase political oversight of federally funded research.

The Coalition for Epidemic Preparedness Innovations (CEPI) also announced new funding for Ebola vaccine development, and the Morning Rounds newsletter highlighted additional health updates.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “CDC says containing the spread of Ebola is top priority”

read at STAT ↗
1,378 words · retrieved Jun 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECAELI LILLY COEli Lilly and CoLILLYModerna, Inc.NOVONovo Nordisk Inc
drugs
Ebola vaccine2Obesity2BPC-157MOUNJAROOzempicWegovyWegovy PillZEPBOUNDtirzepatide
topics
Vaccine8Infectious Disease3Obesity3Vaccines3Drug ShortageGLP-1 receptorPeptide TherapeuticRecallmRNA Therapeutic

related stories

  • Aug 26Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealedBioSpace
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Aug 19Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?BioSpace
  • Aug 27Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive